home / stock / vtyx / vtyx quote
Last: | $2.14 |
---|---|
Change Percent: | 0.88% |
Open: | $2.24 |
Close: | $2.14 |
High: | $2.24 |
Low: | $2.13 |
Volume: | 625,675 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.14 | $2.24 | $2.14 | $2.24 | $2.13 | 625,675 | 07-02-2024 |
$2.26 | $2.37 | $2.26 | $2.37 | $2.175 | 882,481 | 07-01-2024 |
$2.31 | $2.42 | $2.31 | $2.42 | $2.255 | 4,560,759 | 06-28-2024 |
$2.39 | $2.3 | $2.39 | $2.43 | $2.27 | 922,162 | 06-27-2024 |
$2.32 | $2.34 | $2.32 | $2.395 | $2.28 | 706,201 | 06-26-2024 |
$2.39 | $2.52 | $2.39 | $2.5201 | $2.31 | 1,013,895 | 06-25-2024 |
$2.49 | $2.52 | $2.49 | $2.655 | $2.47 | 751,455 | 06-24-2024 |
$2.51 | $2.55 | $2.51 | $2.655 | $2.5 | 1,488,897 | 06-21-2024 |
$2.51 | $2.76 | $2.51 | $2.76 | $2.5 | 699,215 | 06-20-2024 |
$2.75 | $2.75 | $2.75 | $2.87 | $2.7 | 605,989 | 06-19-2024 |
$2.75 | $2.75 | $2.75 | $2.87 | $2.7 | 605,989 | 06-18-2024 |
$2.75 | $2.86 | $2.75 | $2.86 | $2.7 | 912,183 | 06-17-2024 |
$2.88 | $2.84 | $2.88 | $2.9926 | $2.831 | 444,481 | 06-14-2024 |
$2.87 | $3.01 | $2.87 | $3.05 | $2.83 | 891,228 | 06-13-2024 |
$2.98 | $3.2 | $2.98 | $3.4 | $2.92 | 2,751,803 | 06-12-2024 |
$3.2 | $3.35 | $3.2 | $3.3688 | $3.13 | 1,036,211 | 06-11-2024 |
$3.44 | $3.24 | $3.44 | $3.51 | $3.1111 | 1,669,241 | 06-10-2024 |
$3.26 | $3.26 | $3.26 | $3.37 | $3.035 | 1,618,892 | 06-07-2024 |
$3.285 | $4.5 | $3.285 | $4.82 | $3.03 | 6,724,880 | 06-06-2024 |
$5.28 | $4.93 | $5.28 | $5.66 | $4.8 | 3,068,559 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...